Holen Sie sich die Stockscreener-App
57.72
0.17%
-0.10
Schlusskurs vom Vortag:
$57.82
Offen:
$57.82
24-Stunden-Volumen:
12.05M
Relative Volume:
5.65
Marktkapitalisierung:
$1.67B
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-18.92
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+0.05%
1M Leistung:
+69.47%
6M Leistung:
+444.53%
1J Leistung:
+506.30%
1-Tages-Spanne:
$57.71
$57.82
1-Wochen-Bereich:
$57.69
$57.82
52-Wochen-Spanne:
$5.6652
$57.86
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
57.72 | 1.67B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Is RAPT Therapeutics Inc a speculative investmentStop Loss & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Small Cap Stocks To Watch NowFebruary 13th - MarketBeat
Best Pharmaceutical Stocks To Follow TodayFebruary 13th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short Interest - MarketBeat
Can RAPT Therapeutics Inc. withstand a market correctionCPI Data & AI Based Buy and Sell Signals - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? - Morningstar
Top Pharmaceutical Stocks To ConsiderFebruary 10th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Why did RAPT stock surge 63% in pre-market today? - MSN
Pharma deal value falls in January 2026 amid lower M&A activity: GlobalData - Express Pharma
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders - marketscreener.com
RAPT Therapeutics Proposed Sale to GSK Under Investigation - Intellectia AI
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month HighHere's Why - MarketBeat
GSK's Acquisition Highlights Trend Towards Convenience-Focused D - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-JHG, FOLD, RAPT, and EXAS - The Malaysian Reserve
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy - MSN
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—JHG, FOLD, RAPT, and EXAS - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
Rapt Therapeutics stock reaches 52-week high at $57.71 By Investing.com - Investing.com Nigeria
Biggest stock movers Tuesday: NVDA, RAPT, MMM and more - MSN
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 12-Month HighStill a Buy? - MarketBeat
Rapt Therapeutics stock reaches 52-week high at $57.71 - Investing.com
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal - MSN
GSK acquires RAPT Therapeutics for $2.2bn - MSN
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Biggest stock movers Tuesday: NVDA, RAPT, and more - MSN
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
RAPT Therapeutics (RAPT) Receives Downgrade to Equal-Weight by B - GuruFocus
Barclays Reaffirms Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT) - MarketBeat
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
Rapt Therapeutics stock hits 52-week high at $57.62 - Investing.com
RTW Biotech Opp.GSK to acquire RAPT Therapeutics - Research Tree
Leerink Partners Downgrades RAPT Therapeutics(RAPT.US) to Hold Rating, Cuts Target Price to $58 - 富途牛牛
Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech - Blockonomi
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn - European Pharmaceutical Review
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades - Investing.com Nigeria
GSK to buy Rapt Therapeutics in deal valued at $2.2B - MSN
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):